Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401

• Status: Completed
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

An extension study for patients who complete 24 weeks of IMO-8400 on study 8400-401.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Idera Pharmaceuticals, Inc.

Criteria

Inclusion Criteria:

• Completed 24 weeks of treatment in Protocol 8400-401

Exclusion Criteria:

• Grade 3 (or higher) adverse event assessed as treatment-related at any time during the course of treatment under Protocol 8400-401.

• Has evidence of disease progression under Protocol 8400-401.

• Has received other anti-cancer therapies other than IMO-8400 since enrolling in Protocol 8400-401.